title: Effects of Fufang Biejia Ruangan pills on hepatic fibrosis in vivo and in vitro.
abstract: OBJECTIVE
  To explore the protective effect and the relevant mechanisms of Fufang Biejia Ruangan Pills (FFBJRGP) on hepatic fibrosis in vivo and in vitro.
  
  
  METHODS
  Hepatic fibrosis was induced by carbon tetrachloride composite factors. Adult Wistar rats were randomly divided into four groups: normal control group; hepatic fibrosis model group; FFBJRGP-treated group at a daily dose of 0.55 g/kg; and colchicine-treated group at a daily dose of 0.1 g/kg. The effects of FFBJRGP on liver function, serum levels of hyaluronic acid (HA), type IV collagen (CIV), type III procollagen (PC III), laminin (LN), histopathology, and expression of transforming growth factor (TGF-β1) and Smad3 in hepatic fibrosis were evaluated in vivo. The effects of FFBJRGP on survival rate, hydroxyproline content and cell cycle distribution were further detected in vitro.
  
  
  RESULTS
  Compared with the hepatic fibrosis model group, rats treated with FFBJRGP showed a reduction in hepatic collagen deposition and improvement in hepatic lesions. Compared with those of the model group, the activities of alanine aminotransferase (62.0 ± 23.7 U/L) and aspartate aminotransferase (98.8 ± 40.0 U/L) in the FFBJRGP-treated group were decreased (50.02 ± 3.7 U/L and 57.2 ± 30.0 U/L, respectively, P < 0.01). Compared with those in the model group, the levels of PCIII (35.73 ± 17.90 μg/mL), HA (563.82 ± 335.54 ng/mL), LN (89.57 ± 7.59 ng/mL) and CIV (29.20 ± 6.17 ng/mL) were decreased to 30.18 ± 9.41, 456.18 ± 410.83, 85.46 ± 7.51 and 28.02 ± 9.45 ng/mL, respectively. Reverse-transcriptase polymerase chain reaction and Western blotting also revealed that expression of TGF-β1 and Smad3 were down-regulated in vivo. Cell proliferation was inhibited, the level of hydroxyproline was decreased compared with the control group (P < 0.01), and the cell cycle was redistributed when exposed to FFBJRGP in vitro.
  
  
  CONCLUSIONS
  FFBJRGP inhibits hepatic fibrosis in vivo and in vitro, which is probably associated with downregulation of fibrogenic signal transduction of the TGF-β-Smad pathway.
authors: Department of Pharmacology, Tianjin Medical University, Tianjin 300070, China.
authors: Feng-Rui
authors: FR
authors: Yang
authors: Bu-Wu
authors: BW
authors: Fang
authors: Jian-Shi
authors: JS
authors: Lou
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002251:Carbon Tetrachloride; D002453:Cell Cycle / Q000187:drug effects; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D024061:Collagen Type III / Q000097:blood; D024141:Collagen Type IV / Q000097:blood; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D005260:Female; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood; D006909:Hydroxyproline / Q000378:metabolism; D007797:Laminin / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008516:Medicine, Chinese Traditional; D011347:Procollagen / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D051900:Smad3 Protein / Q000378:metabolism; D013607:Tablets; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
chemical_list: D015415:Biomarkers; D024061:Collagen Type III; D024141:Collagen Type IV; D004365:Drugs, Chinese Herbal; D007797:Laminin; D011347:Procollagen; D051900:Smad3 Protein; C497787:Smad3 protein, rat; D013607:Tablets; C508962:Tgfb1 protein, rat; D053773:Transforming Growth Factor beta1; D006820:Hyaluronic Acid; D002251:Carbon Tetrachloride; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D006909:Hydroxyproline
keywords: Fufang Biejia Ruangan Pill; Hepatic fibrosis; Transforming growth factor-Smad signaling
references: J Invest Dermatol. 2002 Feb;118(2):211-5
references: 11841535
references: Cell Signal. 2006 Dec;18(12):2077-88
references: 16824734
references: J Hepatol. 1991 Nov;13(3):372-4
references: 1808228
references: Int J Biochem Cell Biol. 2008;40(3):383-408
references: 18061509
references: Zhonghua Gan Zang Bing Za Zhi. 2004 Apr;12(4):213-5
references: 15099469
references: Am J Transplant. 2006 Jan;6(1):12-9
references: 16433751
references: Clin Gastroenterol Hepatol. 2005 Feb;3(2):95-107
references: 15704042
references: Acta Gastroenterol Belg. 2003 Jan-Mar;66(1):7-14
references: 12812143
references: World J Gastroenterol. 2006 Jan 28;12(4):509-15
references: 16489661
references: J Cell Mol Med. 2006 Jan-Mar;10(1):76-99
references: 16563223
references: Nature. 2003 Oct 9;425(6958):577-84
references: 14534577
references: J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S79-84
references: 17567474
references: Annu Rev Cell Dev Biol. 2005;21:659-93
references: 16212511
references: Biochim Biophys Acta. 2006 Nov-Dec;1759(11-12):503-13
references: 17182123
references: ACS Chem Biol. 2006 Jul 21;1(6):346-8
references: 17163769
references: Mol Cell Biol. 2007 Jun;27(12):4488-99
references: 17438144
references: Curr Opin Cell Biol. 2007 Apr;19(2):176-84
references: 17317136
references: Biochem Soc Trans. 2006 Nov;34(Pt 5):761-3
references: 17052192
references: J Dermatol Sci. 2004 Aug;35(2):83-92
references: 15265520
references: Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 May;26(5):451-4
references: 16883917
references: Front Biosci. 2002 Apr 01;7:d793-807
references: 11897555
references: Hepatology. 2002 Jan;35(1):49-61
references: 11786959
references: Hepatology. 2007 Oct;46(4):1246-56
references: 17625791
references: Cell Growth Differ. 2002 Jun;13(6):265-73
references: 12114216